Table 2.

Reasons patients did not enroll on clinical trials. The distribution of reasons why patients did not enroll on genotype-matched trials following PODS annotations, as stated by the survey respondents.

Reasons patient did not go on trial	All patients (N=161)	Patients with “YES: Literature Based” and “YES: Inferred” variants (N=42)	Patients with variants annotated as “Potentially” actionable (N=29)	Patients with variants annotated as “Unknown” and “No” for actionability (N=90)
Physician stated annotation does not support trial enrollment	71 (44.1%)	5 (11.9%)	9 (31.0%)	57 (63.3%)
Acted on another alteration	9 (5.6%)	2 (4.8%)	3 (10.3%)	4 (4.4%)
Stable disease/Responding on current treatment	21 (13.0%)	6 (14.3%)	8 (27.6%)	7 (7.8%)
Elected local treatment/Elected not to travel	14 (8.7%)	9 (21.4%)	2 (6.9%)	3 (3.3%)
Elected other treatment:	11 (6.8%)	6 (14.3%)	2 (6.9%)	3 (3.3%)
Elected non-investigational treatment	3	1	2	0
Elected non-targeted therapy	2	1	0	1
Enrolled on another trial	5	3	0	2
Screened for trials not relevant to alterations	1	1	0	0
Ineligible:	25 (15.5%)	11 (26.2%)	5 (17.2%)	9 (10.0%)
No measurable disease	2	2	0	0
Active brain metastases	2	1	0	1
Specific morbidities	1	0	1	0
Other morbidities	4	2	1	1
Poor performance status	10	4	1	5
Poor trial candidate – specific comorbidities	6	2	2	2
Deceased	3 (1.9%)	1 (2.4%)	0 (0%)	2 (2.2%)
Eligible, but no slots	2 (1.2%)	1 (2.4%)	0 (0%)	1 (1.1%)
No available trial options	1 (0.6%)	0 (0%)	0 (0%)	1 (1.1%)
Patient did not return for a follow-up appointment	2 (1.2%)	1 (2.4%)	0 (0%)	1 (1.1%)
Previously acted on this alteration	2 (1.2%)	0 (0%)	0 (0%)	2 (2.2%)